Abstract: Methods for enhancing the lysis of coagulated blood comprise administering to coagulated blood a combination of clot clysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof. Methods for reducing the risk of blood coagulation comprise administering to blood a combination of a clot lysis agent and a lysis enhancing amount of Apo E2 or a therapeutic derivative thereof. Additional methods for enhancing the lysis of coagulated blood comprise administering to an individual a specific level of clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the risks of blood coagulation comprise administering to blood a specific level of a clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual.

Abstract: Methods for inhibiting lysis of coagulated blood and reducing risk of excessive lysis comprising administration of lysis-inhibiting amounts of apolipoprotein E4, and methods for inhibiting lysis of coagulated blood and reducing risk of excessive lysis comprising administration of a specific level of a lysis-inhibiting agent wherein the specific level is based on the apolipoprotein phenotype of an individual, are provided. Methods for enhancing lysis of coagulated blood by administration of an Apo E peptide fragment to blood containing a clot lysis agent are also provided.

Abstract: Methods for inhibiting the lysis of coagulated blood comprise administering to blood a lysis-inhibiting amount of apolipoprotein E4 (Apo E4) or a therapeutic derivative thereof. Methods for reducing the risk of excessive blood clot lysis comprise administering the blood a lysis-inhibiting amount of Apo E4 or a therapeutic derivative thereof. Additional methods for inhibiting the lysis of coagulated blood comprise administering to an individual's blood a specific level of a lysis-inhibiting amount of Apo E4 wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the risk of excessive blood clot lysis comprise administering to an individual's blood a specific level of a lysis-inhibiting amount of Apo E4, wherein the specific level is based upon the apolipoprotein phenotype of the individual. Additional methods for enhancing the lysis of coagulated blood comprise administering to blood containing a clot lysis agent an Apo E peptide fragment.

Abstract: Methods for enhancing teh lysis of coagulated blood comprise administering to coagulated blood a combination of clot clysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof. Methods for reducing the risk of blood coagulation comprise administering to blood a combination of a clot lysis agent and a lysis enhancing amount of Apo E2 or a therapeutic derivative thereof. Additional methods for enhancing the lysis of coagulated blood comprise administering to an individual a specific level of clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the riks of blood coagulation comprise administering to blood a specific level of a clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual.